A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus: The PREDICTIVE™ Study: Predictable Results and Experience in Diabetes Through Intensification and Control to Target: an International Variability Evaluation
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Insulin detemir (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms PREDICTIVE
- Sponsors Novo Nordisk
- 06 Dec 2010 Additional trial location (Japan) identified as reported by ClinicalTrials.gov.
- 07 May 2010 Actual patient number (47565) added as reported by ClinicalTrials.gov.
- 07 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.